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DePaul scientists 
work to unravel the 
mystery of chronic 
fatigue syndrome.
By Abigail Pickus
“It’s 
All in 
Your 
Head”
The
ofMyth
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In 1980, a high school English teacher from Wisconsin named Pat Fero went on a trip to England. Healthy and in her 30s, she noticed something was very wrong toward the end of the trip.
“We were in this beautiful countryside, and we went to climb a 
hill to get a better view of a lake and I just couldn’t do it. I thought, 
I am really out of shape. I couldn’t get up that hill. My legs hurt, and 
I was dizzy and short of breath,” recalls Fero.
When she returned home the fever hit.
“I had a 104° fever for a week and a headache from hell. I had 
extreme pain in my neck and shoulders that lasted another week,” 
she says.
Over the next few years she got progressively sicker until she couldn’t 
climb the stairs at school without resting on the landing. Then she 
was unable to write on the chalkboard. “I would misspell things. I 
couldn’t form the letters correctly. I would miss words. Day-to-day 
communication became tough. That’s why I left the classroom. You 
can’t be in front of 20-some kids and seriously not know what you’re 
talking about,” she says. 
In 1988, Fero went on medical leave—and never returned. That 
was the year she finally received a diagnosis for her suffering: chronic 
fatigue syndrome.
Mystery Disease
Tragically, Fero is not alone. Using research data developed at DePaul, 
the Centers for Disease Control  and Prevention (CDC) estimates that 
there are currently more than 1 million people in the U.S. and more 
than 17 million worldwide with chronic fatigue syndrome/myalgic 
encephalomyelitis (CFS/ME)—and these are just the ones who have 
been diagnosed. (See sidebar: What’s in a Name?)
Often triggered by a virus, this debilitating disease continues to 
plague people for years with symptoms that run the gamut from nerve 
pain and cognitive impairments to a fatigue better characterized as 
bone-crushing exhaustion.
“Don’t use the word fatigue. It’s an exhaustion so severe that you 
can’t stand up because you feel like you’re going to faint,” says Fero.
Often lumped together with other so-called “mystery illnesses” 
such as Lyme disease and fibromyalgia, CFS/ME is historically 
misdiagnosed or underdiagnosed simply because one of its defining 
symptoms—fatigue—is both commonplace and seemingly benign. 
Adding insult to injury, CFS/ME is notoriously stigmatized because of 
its name “chronic fatigue,” suggesting that the patient is merely tired. 
But the medical community is baffled, from what causes it to 
what it really is: A brain disease? A virus? And with federal funding 
Research scientists Marcie and Mark Zinn view 3D images 
to identify the sources of dysregulation in the brain.
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for research into CFS/ME improving but still lower than for other 
major diseases, the quality of life for millions of Americans is left 
hanging in the balance.
Enter Leonard Jason, a professor of psychology at DePaul, who 
with his team has been making serious inroads into cracking the 
code on this mystery illness. “DePaul has been trying to validate the 
experience of patients with CFS/ME, to find ways to lessen the burden 
of this illness by reporting on accurate prevalence numbers among 
adults and children, to find effective treatments and to understand 
its etiology,” says Jason. 
It’s a tall order, but with more than 800 professional publications 
and 25 books to his name (many on CFS/ME), plus more than 
$36 million in research grants, Jason and the DePaul Center for 
Community Research have emerged as leading figures in an area of 
medicine otherwise shrouded in darkness.
Center for  
Community Research
Jason has been at DePaul since 1975. Boyish and slender with round 
wire-framed glasses and a friendly manner, he arrived at DePaul 
immediately after receiving his PhD from the University of Rochester, 
having been drawn initially to DePaul because of its values. In fact, his 
area of psychology—clinical community psychology—has distinctly 
Vincentian roots with its emphasis on understanding and addressing 
social problems, particularly for the underserved. It was in this vein 
that Jason founded the Center for Community Research in 2001. 
Jason’s initial interest in CFS/ME was personal. In 1989, he was 
hit with the disease after coming down with mononucleosis, which 
many researchers now feel could be one of the triggers for the illness. It 
took him a full year to feel better, and when he did, he started plowing 
through the meager literature on the disease. What he discovered was 
that he was in a unique position to make a difference. “It just seemed 
like there were so many interesting issues with this illness and that I, 
as a person who had experienced it myself who was also a psychologist 
with a background in strong research methods, could spend a lot of 
time making contributions,” he says. He then pursued the matter from 
all angles, from correcting what he considered to be an inaccurate case 
definition to countering inappropriate CFS/ME myths from some in 
the medical community.
“It was evident to me that there was a lot of stigma against people 
who had what’s called chronic fatigue syndrome, which is not a 
very good term because it is trivializing,” he says. Also trivializing 
were the treatments recommended to patients. “Here you have 
these exhausted and sick people, and you basically want them to do 
exercise and be more active because that’s what you thought would 
help them,” he says.
DePaul Psychology Professor Leonard 
Jason is a leading expert on CFS/ME.
An example of a deregulated network in a person with CFS/ME
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It was Jason’s team who coined the term “staying within the energy 
envelope” as a counter to these popular treatments. In numerous papers, 
Jason showed that for patients with CFS/ME, pushing too hard leads 
to serious consequences known among ME sufferers as post-exertional 
malaise, where the body and brain shut down. 
One of Jason’s most significant contributions to the field has 
been quantifying the number of adults in the U.S. with the disease. 
“The prevalence rates were not very accurate back in the ’90s when I 
first started doing research, and the methodology used by the CDC 
was flawed. At the time, it was considered a rare ‘Yuppie flu’ disease 
primarily affecting white middle-class women. As a result of this myth, 
the federal government did not provide a lot of resources for those 
people who had this illness,” he says.
Throughout the 1990s, Jason and his team conducted a commu-
nity-based epidemiology prevalence study and came to a staggering 
conclusion: Instead of 20,000 Americans with this illness, the number 
was probably closer to a million, and it was actually minorities, 
particularly Hispanics, who were disproportionately affected by the 
disease. The CDC has since updated its figures based on DePaul’s 
research and its own subsequent study. While serving on the CDC’s 
Chronic Fatigue Syndrome Advisory Committee in the mid-2000s, 
Jason was able to make recommendations to the Secretary of U.S. 
Health and Human Services about the research and service needs of 
this patient group.
Mapping Brainwaves
One sunny, summer afternoon, research scientists Marcie and Mark 
Zinn were hard at work in the laboratory they fashioned inside DePaul’s 
Center for Community Research to view images created by quantitative 
electroencephalography (qEEG) that maps the brain waves of people 
with CFS/ME. Pointing to two computer monitors displaying a 3D 
cross section of the brain alongside the EEG squiggles tracking the 
brain’s metabolic activity, Marcie shows how the technology uses 
low-resolution electromagnetic tomography (LORETA) software to 
estimate the sources in the brain causing its dysregulation. It does this 
all at the millisecond level, the time frame in which the brain actually 
operates—a vast improvement over the functional MRI, which has 
a 2- to 3-second delay.
“A normally functioning brain depends on the neurons functioning 
within a certain time frame. For patients with ME, the neurons are 
either damaged or dead, which causes cognitive impairments because 
of the slowed speed and the first part of the processing hasn’t been 
resolved before they move on to the next,” says Marcie. 
qEEG was developed by Clinical Neuroscience Professor Robert 
Thatcher, who uses it to examine all types of brain injuries; it is also 
used to study the brains of those with autism and traumatic brain 
injury. DePaul is the only research center in the world using qEEG 
to link communication between neural networks and the cognitive 
dysregulation of patients with CFS/ME. This is something the Zinns 
hope will change.
“Right now it’s very hard to measure ME, which makes it hard to 
diagnose. People either have to go to an infectious diseases doctor or 
[we] have to wait until they’re dead for their brains to be autopsied.
“One of the things we’re trying to work on is for doctors to use 
our technology in their offices to help potential patients with ME,” 
says Marcie, adding that the diagnostic procedures used currently are 
only accurate in about 50 percent of the cases.
“The prevalence rates 
were not very accurate 
back in the ’90s when 
I first started doing 
research, and the 
methodology used by 
the CDC was flawed.”
Leonard Jason
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The Zinns began using qEEG in 2001 to study the brain patterns 
of concert pianists, a profession they both pursued before switching to 
careers in psychology. They transitioned to studying patients with CFS/
ME in 2010 at Stanford University under Jose Montoya, an infectious 
disease doctor, and have continued their work since joining DePaul in 
2015. Marcie is the former director of  the center’s cognitive systems 
neuroscience unit, and Mark is pursuing a PhD in community psychology.
They have studied the brains of more than 200 patients with ME/
CFS and have published many research articles on different aspects 
of the disease. Among their discoveries is that post-exertional malaise 
is truly all in patients’ heads—just not in the way doctors thought. 
“Their brain function literally tanks. We can actually see that,” says 
Marcie. They’ve also seen how CFS/ME patients’ everyday waking 
brain is drowsy because of too many delta waves.
All these findings have given those suffering from the disease the kind 
of validation they have long sought. “To see your brain light up like a 
Christmas tree when you do a simple task really validates what I already 
know,” says Fero, who came to DePaul to participate in the studies. “I 
didn’t think I wasn’t able to write on the chalkboard because there was 
some psychiatric problem. I knew there was something wrong with my 
brain. These 3D scans confirm that.”
For Marcie, who also suffers from the disease, focusing on the 
brain is a significant step in the right direction particularly because 
blood tests cannot detect CFS/ME. “Just because a doctor doesn’t 
find any indicators of illness in a person’s blood doesn’t mean they 
aren’t sick. It just means they aren’t looking where the problem is,” 
says Marcie. 
The Invisible Demographic
“I really don’t want to die, but it’s really hard to call this living,” says 
CFS/ME patient Jennifer Brea in her chilling documentary, “Unrest,” 
which documents just how widespread—and debilitating—the disease 
is. Some of the most heart-wrenching stories in the film are about 
young people who have spent most of their formative years bedridden. 
It turns out that children are the most invisible demographic to be 
hit by CFS/ME. Only Jason and his team are putting a number on 
this phenomenon. They are currently wrapping up a rigorous study 
of 10,000 children to estimate its prevalence among youth.
“Sometimes there are children who are functioning at a very high 
level and then all of a sudden something happens—there’s an accident 
or there might be some type of virus, we’re still trying to understand 
Volunteers with CFS/ME come to DePaul’s Center for Community Research to participate in 
studies during which a special cap measures their brain waves, and a software program called 
eLORETA links communication between neural networks and cognitive dysregulation.
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What’s in a Name?
In the second half of the 19th century, 
a new epidemic spread across the 
country: Women of the upper and 
middle classes were taking to their 
beds with fatigue and weakness. It 
was neurologist George Miller Beard 
who gave this condition a name: 
neurasthenia. He blamed the malady 
on the modern predicament of 
“American nervousness.” 
Despite a rash of outbreaks 
reported around the world beginning 
in the 1930s, it wasn’t until a 1955 
outbreak in London that this mystery 
disease was given a more scientific 
diagnosis: myalgic encephalomyelitis 
(ME), which means inflammation of 
the brain. 
But the Centers for Disease Control 
and Prevention (CDC) reversed all 
that in 1984 after yet another out-
break in Lake Tahoe, Nev., when they 
dubbed the condition chronic fatigue 
syndrome (CFS).
“When we gave medical interns the 
name ‘chronic fatigue syndrome’ with 
a prototypical person with this illness 
versus a medical sounding term 
(myalgic encephalopathy), we found 
there was judgment when they saw 
‘chronic fatigue’ because it seemed 
psychological. If you called something 
chronic cough syndrome, they’d say, 
‘So what? Everyone coughs.’ But if 
you called it bronchitis or emphyse-
ma, then people would say, ‘This is 
important,’” says DePaul Psychology 
Professor Leonard Jason, who is a 
leading authority on CFS/ME.
That’s why so many patients prefer 
the term myalgic encephalomyelitis. 
“It’s a brain infection,” says Marcie 
Zinn, a psychologist who conduct-
ed CFS/ME research at the DePaul 
Center for Community Research. “So 
many people still think the disease is 
in your head, so the diagnosis really 
needs to be more clinical; otherwise 
people with the disease are left 
fighting two battles: the disease itself 
and public perception.”
Instead of 20,000 Americans 
with CFS/ME, the number is 
probably closer to a million, 
according to DePaul’s Center 
for Community Research.
that—and then their functioning goes down considerably. Their 
parents and school officials often think, ‘Is this child just malingering?’ 
Unless there is an ally to help the child, the child could easily get 
stigmatized for this condition,” says Jason.
In another prospective longitudinal study, Ben Katz, a professor 
of pediatrics at Northwestern’s Feinberg School of Medicine, is 
partnering with Jason to look at the link between mononucleosis, 
which is triggered by the Epstein-Barr virus, and CFS/ME in youth. 
The study looks at which percentage of those who develop mono 
will go on to develop CFS/ME and why. “About 5 percent of all kids 
who go to college will get mono before they graduate, and about 12 
percent who get mono will meet criteria for CFS/ME six months 
later,” says Katz. “Why do most people recover? Nobody knows the 
answer, and that’s why we decided to study college kids. By enrolling 
people when they’re healthy, you can see if they get mono and why 
some recover and some don’t.”
Data collection to estimate the prevalence of CFS/ME among youth 
will be completed in 2019, and soon after, papers will be submitted 
for publication, according to Jason. The results of the mono-CFS/
ME study will also be released in 2019. 
“This is an exciting study as we are getting close to finding out 
some kind of answers,” adds Katz. 
On the Brink of a Breakthrough
Answers are exactly what people like Fero need. “I am almost 69, 
and I’ve had this for more than half my life,” she says. She’s buoyed, 
however, by a changing tide of events, from an emboldened sense of 
advocacy among patients through the power of social media to the 
growing number of institutions working to find some answers. Stanford 
University, for example, has created both an initiative to study CFS/
ME and a CFS research center under the direction of Ronald Davis, 
a professor of biochemistry and genetics whose son has a severe case 
of the disease.
“Are we getting closer to a breakthrough?” Jason asks. “I think 
so, yes.”
